OMCL logo

OMCLOmnicell, Inc.

$41.89
$0.02
(0.05%)
Today
Closed $41.89
$0.00
(0.00%)
After Hours
Updated: 04:11 PM EDT
EarningsJul 30
Mkt Cap$1.91B
Vol539,856.00
News
all
press releases
Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Omnicell, Inc. (Nasdaq:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, announced that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026, at 3:20 PM EDT. Live and archived webcasts of...
Business Wire
News Placeholder
More News
News Placeholder
Omnicell (OMCL) Up 0.1% Since Last Earnings Report: Can It Continue?
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Omnicell Stock Surges 57.3% in a Year: What's Driving It?
OMCL shares soar 57.3% in a year as SaaS growth, Autonomous Pharmacy momentum and OmniSphere adoption boost outlook.
Zacks
News Placeholder
Should You Buy Omnicell (OMCL) After Golden Cross?
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
Zacks
News Placeholder
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.
Zacks
News Placeholder
How Much Upside is Left in Omnicell (OMCL)? Wall Street Analysts Think 39.87%
The average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in Omnicell (OMCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
News Placeholder
Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)
Here is What Analysts Are Saying About Omnicell, Inc. (OMCL...
Yahoo! Finance: News
News Placeholder
Can Platform Expansion Support Hims & Hers Stock Before Q1 Earnings?
HIMS first-quarter 2026 results are likely to benefit from Labs and branded weight loss medications even as higher costs and GLP-1 scrutiny linger.
Zacks
News Placeholder
Here's Why Omnicell (OMCL) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
News Placeholder
DaVita Stock Up Following Q1 Earnings & Revenue Beat, Margins Expand
DVA's first-quarter 2026 results benefit from expanding margins and steady dialysis demand across its broad clinic network.
Zacks
<
1
2
...
>